"We expect to enhance HERmark during 2009 with clinical data related to Herceptin response upon completion of ongoing and planned clinical studies," added Young. "Also in 2009, our goal is to further expand HERmark with the planned introduction of an additional marker to HERmark that may inform decisions about potential combination therapy, not just Herceptin therapy."
VeraTag(TM) Oncology Platform
"With our VeraTag platform, we can make precise and quantitative measurements of protein complexes that have not previously been possible," said Gordon Parry, Ph.D., Monogram vice president of research & development, oncology. "With an expanding set of EGFR/HER assays, we expect to enhance our current commercially available product, the HERmark Breast Cancer Assay, and also pursue opportunities for use of VeraTag assays in drug development programs in many other cancer types."
Monogram has a growing portfolio of VeraTag assays that measure proteins, protein complexes and post-translational modifications such as phosphorylation, in FFPE tumor samples. This month, Monogram scientists presented data on the HER1 and HER3 total protein assays, the HER1:HER1 homodimer assay and the activated HER1:HER2 heterodimer assay, at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland. Data on the HER2:HER3 heterodimer assay and the HER3:PI3K assay will be presented at the AACR "Targeting the PI3-Kinase Pathway in Cancer" meeting in Cambridge, MA in November. An assay for the truncated form of HER2, known as p95, is in advanced development.
GAAP and Non-GAAP Proforma Results
Net Loss and Net Loss Per Sh
|SOURCE Monogram Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved